U.S. House Committee's Investigation into Chinese Clinical Trials Raises Concerns about Supply Chain Restructuring and Increased Regulatory Costs for Pfizer, BMS, and Other Major Pharma Companies
U.S. Congressional Investigation into Chinese Clinical Trials and Geopolitical Risks
The U.S. House Select Committee on China, led by Chairman John Moolenaar, has sent warning letters to major global pharmaceutical companies such as Pfizer (PFE), Merck & Co. (MRK), Bristol Myers Squibb (BMY), and AbbVie (ABBV). These letters allege that these companies are conducting clinical trials in the Xinjiang Uyghur Autonomous Region of China and utilizing medical institutions affiliated with the People's Liberation Army (PLA), potentially compromising the security of biological data. This signifies a shift in U.S. legislative oversight, extending beyond manufacturing and supply chains to encompass the critical clinical phase of drug development. Consequently, the trend of geopolitical decoupling, aimed at reducing reliance on China within the global bio-ecosystem, is likely to accelerate.
Regulatory Burden Spreads from Big Pharma to Smaller Biotech Companies
This investigation extends beyond the Xinjiang region, comprehensively addressing the transparency and ethical responsibility of global clinical data. While large pharmaceutical companies like Pfizer and BMS can absorb the legal and logistical costs associated with regulatory changes and redesigning clinical networks, smaller biotech startups face a potentially existential crisis. These startups, which rely on securing substantial funding for early-stage clinical proof-of-concept studies, may experience delays in their research and development (R&D) timelines as they navigate more complex regulatory due diligence and legal risks.
Restructuring of the Global Clinical Trial Contract Research Organization (CRO) Market Supply Chain
China has long been an attractive location for global clinical trials due to its large patient population, lower costs, and faster trial initiation. However, with the realization of regulatory risks, major venture capital (VC) firms like Santé Ventures and biotech companies have begun actively exploring the relocation of their clinical trial CRO networks to regions with lower geopolitical risks, such as Australia, Japan, South Korea, Singapore, and Europe. The sudden shift in clinical trial locations disrupts the continuity of existing patient data and requires additional trial approval procedures, resulting in significant costs and delays. This will ultimately lead to a surge in demand and price increases in alternative CRO markets within the Asia-Pacific region, fundamentally altering the cost structure of global drug development.
Uncertainty in Immuno-Oncology Licensing Deals and the Obesity Treatment Market
The letters specify that early-stage clinical trials of drugs in-licensed from Chinese biotech companies will be exempt from regulatory review. However, the market is closely monitoring the future global pipeline clinical schedules of companies like Bristol Myers Squibb (BMY), which entered into a $15.2 billion licensing agreement with Jiangsu Hengrui Pharmaceuticals in May 2026 for 13 early-stage programs, and Kailera Therapeutics (KLRA), which successfully completed a $625 million initial public offering (IPO) by in-licensing Hengrui's obesity pipeline. If the management of risks associated with Chinese partner institutions in global Phase 3 trials of obesity drug candidates like ribupatide (KAI-9531) is inadequate, it could lead to regulatory disapproval. Therefore, the verification of the regulatory legitimacy of Chinese assets will become a key determinant of success in future bio-deals.
The U.S. House Committee's clinical trial investigation is directly impacting the clinical strategies of global Big Pharma companies like Pfizer (PFE) and BMS (BMY), as well as emerging biotech companies exploring clinical site transfers to countries like Australia and South Korea. Specifically, BMY's 13 pipeline programs, which are part of a $15.2 billion licensing agreement with Jiangsu Hengrui Pharmaceuticals in May 2026, and Kailera Therapeutics' (KLRA) ribupatide (KAI-9531) Phase 3 trial, which raised $625 million through an IPO, face potential delays in their long-term commercialization schedules depending on regulatory compliance. Researchers anticipate that shifting away from China-centric multinational clinical trial designs, which offer faster patient recruitment and cost-effectiveness, to alternative countries with CROs will increase initial clinical costs by more than 30%. As a result, industry professionals and venture capital (VC) firms will face additional regulatory cost burdens by thoroughly verifying the early clinical site history of Chinese assets during the due diligence phase, which will likely affect the valuation of future cross-border licensing deals.